Patents by Inventor Claire Louise Dobson
Claire Louise Dobson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220251204Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.Type: ApplicationFiled: December 14, 2021Publication date: August 11, 2022Inventors: Srinath KASTURIRANGAN, Changshou GAO, Godfrey RAINEY, Michelle MORROW, Claire Louise DOBSON, Stacey DRABIC, Darren SCHOFIELD, Gianluca CARLESSO, Kristen POLLIZZI, Yariv MAZOR, Michael OBERST, Scott A. HAMMOND, Brian LOBO, Prakash MANIKWAR, Jonathan SEAMAN, Simon DOVEDI, Ronald HERBST
-
Patent number: 11279759Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.Type: GrantFiled: September 13, 2019Date of Patent: March 22, 2022Assignee: MedImmune, LLCInventors: Srinath Kasturirangan, Changshou Gao, Godfrey Rainey, Michelle Morrow, Claire Louise Dobson, Stacey Drabic, Darren Schofield, Gianluca Carlesso, Kristen Pollizzi, Yariv Mazor, Michael Oberst, Scott A. Hammond, Brian Lobo, Prakash Manikwar, Jonathan Seaman, Simon Dovedi, Ronald Herbst
-
Publication number: 20200172622Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.Type: ApplicationFiled: September 13, 2019Publication date: June 4, 2020Inventors: SRINATH KASTURIRANGAN, CHANGSHOU GAO, GODFREY RAINEY, MICHELLE MORROW, CLAIRE LOUISE DOBSON, STACEY DRABIC, DARREN SCHOFIELD, GIANLUCA CARLESSO, KRISTEN POLLIZZI, YARIV MAZOR, MICHAEL OBERST, SCOTT A. HAMMOND, BRIAN LOBO, PRAKASH MANIKWAR, JONATHAN SEAMAN, SIMON DOVEDI, RONALD HERBST
-
Patent number: 10457732Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.Type: GrantFiled: May 5, 2017Date of Patent: October 29, 2019Assignee: MEDIMMUNE, LLCInventors: Srinath Kasturirangan, Changshou Gao, Godfrey Rainey, Michelle Morrow, Claire Louise Dobson, Stacey Drabic, Darren Schofield, Gianluca Carlesso, Kristen Pollizzi, Yariv Mazor, Michael Oberst, Scott A. Hammond, Brian Lobo, Prakash Manikwar, Jonathan Seaman, Simon Dovedi, Ronald Herbst
-
Publication number: 20180327502Abstract: Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4R?), and their therapeutic use e.g. in treating or preventing disorders associated with IL-4R?, IL-4 and/or IL-13, examples of which are asthma and COPD.Type: ApplicationFiled: July 17, 2018Publication date: November 15, 2018Inventors: Per-Olof Fredrik Eriksson, Karin Von Wachenfeldt, Emma Suzanne Cohen, Claire Louise Dobson, Deborah Louise Lane
-
Publication number: 20180057596Abstract: Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4R?), and their therapeutic use e.g., in treating or preventing disorders associated with IL-4R?, IL-4 and/or IL-13, examples of which are asthma and COPD.Type: ApplicationFiled: January 24, 2017Publication date: March 1, 2018Inventors: Per-Olof Fredrik Eriksson, Karin Von Wachenfeldt, Emma Suzanne Cohen, Claire Louise Dobson, Deborah Louise Lane
-
Publication number: 20180022807Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.Type: ApplicationFiled: May 5, 2017Publication date: January 25, 2018Applicant: MEDIMMUNE, LLCInventors: Srinath KASTURIRANGAN, CHANGSHOU GAO, GODFREY RAINEY, MICHELLE MORROW, CLAIRE LOUISE DOBSON, STACEY DRABIC, DARREN SCHOFIELD, GIANLUCA CARLESSO, KRISTEN POLLIZZI, YARIV MAZOR, MICHAEL OBERST, SCOTT A. HAMMOND, BRIAN LOBO, PRAKASH MANIKWAR, JONATHAN SEAMAN
-
Publication number: 20170281769Abstract: The present invention relates to a stable, low viscosity antibody formulation, wherein the formulation comprises a high concentration of anti-IL4R antibody. In some embodiments, the invention relates in general to a stable antibody formulation comprising about 100 mg/mL to about 200 mg/mL of an antibody or fragment thereof that specifically binds human interleukin-4 receptor alpha (hIL-4R?), about 50 mM to about 400 mM of a viscosity modifier; about 0.002% to about 0.2% of a non-ionic surfactant; and a formulation buffer. In some embodiments, the formulation buffer is essentially free of phosphate. In some embodiments, the invention is directed to a container, dosage form and/or kit. In some embodiments, the invention is directed to a method of making and using the stable antibody formulation.Type: ApplicationFiled: September 2, 2015Publication date: October 5, 2017Inventors: Per-Olof Fredrik Eriksson, Karin Von Wachenfeldt, Suzanne Cohen, Claire Louise Dobson, Deborah Louise Lane, Katrina Day
-
Patent number: 9587027Abstract: Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4R?), and their therapeutic use e.g. in treating or preventing disorders associated with IL-4R?, IL-4 and/or IL-13, examples of which are asthma and COPD.Type: GrantFiled: September 24, 2014Date of Patent: March 7, 2017Assignee: MEDIMMUNE LIMITEDInventors: Per-Olof Fredrik Eriksson, Karin Von Wachenfeldt, Emma Suzanne Cohen, Claire Louise Dobson, Deborah Louise Lane
-
Publication number: 20150079092Abstract: Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4R?), and their therapeutic use e.g. in treating or preventing disorders associated with IL-4R?, IL-4 and/or IL-13, examples of which are asthma and COPD.Type: ApplicationFiled: September 24, 2014Publication date: March 19, 2015Inventors: Per-Olof Fredrik Eriksson, Karin Von Wachenfeldt, Suzanne Cohen, Claire Louise Dobson, Deborah Louise Lane
-
Patent number: 8877189Abstract: Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4R?), and their therapeutic use e.g. in treating or preventing disorders associated with IL-4R?, IL-4 and/or IL-13, examples of which are asthma and COPD.Type: GrantFiled: June 6, 2013Date of Patent: November 4, 2014Assignee: MedImmune LimitedInventors: Per-Olof Fredrik Eriksson, Karin Von Wachenfeldt, Suzanne Cohen, Claire Louise Dobson, Deborah Louise Lane
-
Publication number: 20130336978Abstract: Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4R?), and their therapeutic use e.g. in treating or preventing disorders associated with IL-4R?, IL-4 and/or IL-13, examples of which are asthma and COPD.Type: ApplicationFiled: June 6, 2013Publication date: December 19, 2013Inventors: Per-Olof Fredrik Eriksson, Karin Von Wachenfeldt, Suzanne Cohen, Claire Louise Dobson, Deborah Louise Lane
-
Publication number: 20120171197Abstract: Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4R?), and their therapeutic use e.g. in treating or preventing disorders associated with IL-4R?, IL-4 and/or IL-13, examples of which are asthma and COPD.Type: ApplicationFiled: December 6, 2011Publication date: July 5, 2012Applicant: MEDIMMUNE LIMITEDInventors: PER-OLOF FREDRIK ERIKSSON, KARIN VON WACHENFELDT, SUZANNE COHEN, CLAIRE LOUISE DOBSON, DEBORAH LOUISE LANE
-
Patent number: 8092804Abstract: Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4R?), and their therapeutic use e.g. in treating or preventing disorders associated with IL-4R?, IL-4 and/or IL-13, examples of which are asthma and COPD.Type: GrantFiled: December 18, 2008Date of Patent: January 10, 2012Assignee: MedImmune LimitedInventors: Per-Olof Fredrik Eriksson, Karin Von Wachenfeldt, Suzanne Cohen, Claire Louise Dobson, Deborah Louise Lane
-
Patent number: 7959917Abstract: This invention relates to binding members, especially antibody molecules, for IgE. The binding members are useful for, inter alia, treatment of disorders mediated by IgE including allergies and asthma.Type: GrantFiled: February 15, 2008Date of Patent: June 14, 2011Assignee: MedImmune LimitedInventors: Duncan Cochrane, Suzanne Cohen, Claire Louise Dobson, Per-Olof Eriksson, Karin Von Wachenfeldt, Phillip David Monk
-
Publication number: 20090202568Abstract: Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4R?), and their therapeutic use e.g. in treating or preventing disorders associated with IL-4R?, IL-4 and/or IL-13, examples of which are asthma and COPD.Type: ApplicationFiled: December 18, 2008Publication date: August 13, 2009Applicant: AstraZeneca ABInventors: Per-Olof Fredrik Eriksson, Karin Von Wachenfeldt, Suzanne Cohen, Claire Louise Dobson, Deborah Louise Lane
-
Publication number: 20090060919Abstract: This invention relates to binding members, especially antibody molecules, for IgE. The binding members are useful for, inter alia, treatment of disorders mediated by IgE including allergies and asthma.Type: ApplicationFiled: February 15, 2008Publication date: March 5, 2009Applicant: ASTRAZENECA ABInventors: Duncan Cochrane, Suzanne Cohen, Claire Louise Dobson, Per-Olof Eriksson, Karin Von Wachenfeldt, Phillip David Monk
-
Patent number: RE49908Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.Type: GrantFiled: June 30, 2021Date of Patent: April 9, 2024Assignee: MedImmune, LLCInventors: Srinath Kasturirangan, Changshou Gao, Godfrey Rainey, Michelle Morrow, Claire Louise Dobson, Stacey Drabic, Darren Schofield, Gianluca Carlesso, Kristen Pollizzi, Yariv Mazor, Michael Oberst, Scott A. Hammond, Brian Lobo, Prakash Manikwar, Jonathan Seaman, Simon Dovedi, Ronald Herbst